H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH

H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH

Abstract NASH is characterized by hepatic lipid accumulation and inflammation; and JMJD2B—a histone demethylase—upregulation has been linked to its progression. Pirfenidone (PFD) is an antifibrotic agent with anti-inflammatory and antioxidant effects recognized to decrease NASH symptoms. Herein, our...

Full description

Bibliographic Details
Main Authors: J. Samael Rodriguez-Sanabria, Rebeca Rosas-Campos, Ángel Vázquez-Esqueda, Ivonne Palacios-Marín, Josep Jiménez-Chillaron, Rebeca Escutia-Gutiérrez, Luis Felipe Jave-Suarez, Marina Galicia-Moreno, Hugo Christian Monroy-Ramirez, Eira Cerda-Reyes, Mónica Almeida-López, Erika Martinez-Lopez, Luis Alonso Herrera, Juan Armendáriz-Borunda, Ana Sandoval-Rodriguez
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
MASLD
H3K9
JMJD2B
Pirfenidone
Online Access:https://doi.org/10.1038/s41598-024-75458-2

Internet

https://doi.org/10.1038/s41598-024-75458-2

Similar Items